Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease

Masato Ikeda, Masatsugu Nakao, Keita Hirano, Keitaro Yokoyama, Takashi Yokoo, Nobuhiko Joki, Ryoichi Ando, Toshio Shinoda, Daijo Inaguma, Toshihiko Yamaka, Yasuhiro Komatsu, Fumihiko Koiwa, Toshifumi Sakaguchi, Shigeo Negi, Takashi Shigematsu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Preventive medications for dialysis-requiring congestive heart failure (CHF) in non-dialysis Japanese patients with Stage 5 chronic kidney disease (CKD) are unknown. Our aim was to explore which CKD medication was associated with a reduced prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Methods: The present multicenter, retrospective, cross-sectional study examined the association between CKD medications and the prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Results: There were 1536 Japanese Stage 5 CKD patients who satisfied our inclusion criteria. We had 309 (20.1%) patients whom had developed dialysis-requiring CHF and 940 patients (60.8%) whom had been using angiotensin-II receptor blockers (ARBs) before initiating dialysis. In our multivariate analysis, only ARB use was significantly associated with a lower risk of CHF (Odds ratio (OR): 0.680, 95% confidence interval (CI): 0.516-0.897; p = 0.0064), of the CKD treatments examined in this study. Conclusions: We found that ARB use during the pre-dialysis period is associated with a lower prevalence of CHF in the non-dialysis Japanese patients with Stage 5 CKD, suggesting a possible prevention of dialysis-requiring CHF by ARBs, in non-dialysis Japanese patients with Stage 5 CKD.

Original languageEnglish
Pages (from-to)1175-1184
Number of pages10
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Volume16
Issue number4
DOIs
Publication statusPublished - 01-12-2015

Fingerprint

Angiotensin Receptor Antagonists
Chronic Renal Insufficiency
Dialysis
Heart Failure
Multivariate Analysis
Cross-Sectional Studies
Odds Ratio
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology

Cite this

Ikeda, Masato ; Nakao, Masatsugu ; Hirano, Keita ; Yokoyama, Keitaro ; Yokoo, Takashi ; Joki, Nobuhiko ; Ando, Ryoichi ; Shinoda, Toshio ; Inaguma, Daijo ; Yamaka, Toshihiko ; Komatsu, Yasuhiro ; Koiwa, Fumihiko ; Sakaguchi, Toshifumi ; Negi, Shigeo ; Shigematsu, Takashi. / Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease. In: JRAAS - Journal of the Renin-Angiotensin-Aldosterone System. 2015 ; Vol. 16, No. 4. pp. 1175-1184.
@article{da387d97bdf34b12ae23b65ffb4931f7,
title = "Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease",
abstract = "Background: Preventive medications for dialysis-requiring congestive heart failure (CHF) in non-dialysis Japanese patients with Stage 5 chronic kidney disease (CKD) are unknown. Our aim was to explore which CKD medication was associated with a reduced prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Methods: The present multicenter, retrospective, cross-sectional study examined the association between CKD medications and the prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Results: There were 1536 Japanese Stage 5 CKD patients who satisfied our inclusion criteria. We had 309 (20.1{\%}) patients whom had developed dialysis-requiring CHF and 940 patients (60.8{\%}) whom had been using angiotensin-II receptor blockers (ARBs) before initiating dialysis. In our multivariate analysis, only ARB use was significantly associated with a lower risk of CHF (Odds ratio (OR): 0.680, 95{\%} confidence interval (CI): 0.516-0.897; p = 0.0064), of the CKD treatments examined in this study. Conclusions: We found that ARB use during the pre-dialysis period is associated with a lower prevalence of CHF in the non-dialysis Japanese patients with Stage 5 CKD, suggesting a possible prevention of dialysis-requiring CHF by ARBs, in non-dialysis Japanese patients with Stage 5 CKD.",
author = "Masato Ikeda and Masatsugu Nakao and Keita Hirano and Keitaro Yokoyama and Takashi Yokoo and Nobuhiko Joki and Ryoichi Ando and Toshio Shinoda and Daijo Inaguma and Toshihiko Yamaka and Yasuhiro Komatsu and Fumihiko Koiwa and Toshifumi Sakaguchi and Shigeo Negi and Takashi Shigematsu",
year = "2015",
month = "12",
day = "1",
doi = "10.1177/1470320315592565",
language = "English",
volume = "16",
pages = "1175--1184",
journal = "JRAAS - Journal of the Renin-Angiotensin-Aldosterone System",
issn = "1470-3203",
publisher = "SAGE Publications Ltd",
number = "4",

}

Ikeda, M, Nakao, M, Hirano, K, Yokoyama, K, Yokoo, T, Joki, N, Ando, R, Shinoda, T, Inaguma, D, Yamaka, T, Komatsu, Y, Koiwa, F, Sakaguchi, T, Negi, S & Shigematsu, T 2015, 'Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease', JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, vol. 16, no. 4, pp. 1175-1184. https://doi.org/10.1177/1470320315592565

Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease. / Ikeda, Masato; Nakao, Masatsugu; Hirano, Keita; Yokoyama, Keitaro; Yokoo, Takashi; Joki, Nobuhiko; Ando, Ryoichi; Shinoda, Toshio; Inaguma, Daijo; Yamaka, Toshihiko; Komatsu, Yasuhiro; Koiwa, Fumihiko; Sakaguchi, Toshifumi; Negi, Shigeo; Shigematsu, Takashi.

In: JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, Vol. 16, No. 4, 01.12.2015, p. 1175-1184.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Possible prevention of dialysis-requiring congestive heart failure by angiotensin-II receptor blockers in non-dialysis Japanese patients with Stage 5 chronic kidney disease

AU - Ikeda, Masato

AU - Nakao, Masatsugu

AU - Hirano, Keita

AU - Yokoyama, Keitaro

AU - Yokoo, Takashi

AU - Joki, Nobuhiko

AU - Ando, Ryoichi

AU - Shinoda, Toshio

AU - Inaguma, Daijo

AU - Yamaka, Toshihiko

AU - Komatsu, Yasuhiro

AU - Koiwa, Fumihiko

AU - Sakaguchi, Toshifumi

AU - Negi, Shigeo

AU - Shigematsu, Takashi

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: Preventive medications for dialysis-requiring congestive heart failure (CHF) in non-dialysis Japanese patients with Stage 5 chronic kidney disease (CKD) are unknown. Our aim was to explore which CKD medication was associated with a reduced prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Methods: The present multicenter, retrospective, cross-sectional study examined the association between CKD medications and the prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Results: There were 1536 Japanese Stage 5 CKD patients who satisfied our inclusion criteria. We had 309 (20.1%) patients whom had developed dialysis-requiring CHF and 940 patients (60.8%) whom had been using angiotensin-II receptor blockers (ARBs) before initiating dialysis. In our multivariate analysis, only ARB use was significantly associated with a lower risk of CHF (Odds ratio (OR): 0.680, 95% confidence interval (CI): 0.516-0.897; p = 0.0064), of the CKD treatments examined in this study. Conclusions: We found that ARB use during the pre-dialysis period is associated with a lower prevalence of CHF in the non-dialysis Japanese patients with Stage 5 CKD, suggesting a possible prevention of dialysis-requiring CHF by ARBs, in non-dialysis Japanese patients with Stage 5 CKD.

AB - Background: Preventive medications for dialysis-requiring congestive heart failure (CHF) in non-dialysis Japanese patients with Stage 5 chronic kidney disease (CKD) are unknown. Our aim was to explore which CKD medication was associated with a reduced prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Methods: The present multicenter, retrospective, cross-sectional study examined the association between CKD medications and the prevalence of dialysis-requiring CHF in non-dialysis Japanese patients with Stage 5 CKD. Results: There were 1536 Japanese Stage 5 CKD patients who satisfied our inclusion criteria. We had 309 (20.1%) patients whom had developed dialysis-requiring CHF and 940 patients (60.8%) whom had been using angiotensin-II receptor blockers (ARBs) before initiating dialysis. In our multivariate analysis, only ARB use was significantly associated with a lower risk of CHF (Odds ratio (OR): 0.680, 95% confidence interval (CI): 0.516-0.897; p = 0.0064), of the CKD treatments examined in this study. Conclusions: We found that ARB use during the pre-dialysis period is associated with a lower prevalence of CHF in the non-dialysis Japanese patients with Stage 5 CKD, suggesting a possible prevention of dialysis-requiring CHF by ARBs, in non-dialysis Japanese patients with Stage 5 CKD.

UR - http://www.scopus.com/inward/record.url?scp=84952929032&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952929032&partnerID=8YFLogxK

U2 - 10.1177/1470320315592565

DO - 10.1177/1470320315592565

M3 - Article

VL - 16

SP - 1175

EP - 1184

JO - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

JF - JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

SN - 1470-3203

IS - 4

ER -